The Worldwide Recombinant Proteins Industry is Expected to Reach $5 Billion by 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Recombinant Proteins Market Size, Share & Trends Analysis Report by Host Cell (Insect Cells, Mammalian), by Application (Research, Therapeutics), by Product & Services, by End-user, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.

The global recombinant proteins market size is expected to reach USD 5.09 billion by 2030, registering a CAGR of 12.0% over the forecast period, according to this report.

Companies Mentioned

• Thermo Fisher Scientific, Inc.
• Abcam plc
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• R&D Systems
• Merck KGaA
• GenScript Biotech Corporation
• RayBiotech Life, Inc.
• Proteintech Group, Inc.
• Enzo Life Sciences, Inc.
• STEMCELL Technologies Inc
• Sino Biological, Inc.
• Abnova Corporation

Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion.

Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19.

Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The rise in pharmaceutical firms’ R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections are the main drivers of the global industry.

Recombinant Proteins Market Report Highlights

• By product & services, the product segment accounted for the largest revenue share in 2021. The demand is increasing globally due to the need for recombinant protein products in biomedical research and increased funding for R&D in the fight against cancer
• The therapeutics application segment held the maximum revenue share in 2021 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases
• The pharma & biotech companies end-user segment led the global industry in 2021 due to the increasing investments by key market players in their R&D segment to increase research productivity and grow their offerings for revenue generation
• Mammalian systems are widely used in the production of recombinant proteins, thus, this segment accounted for the largest revenue share in 2021
• North America was the dominant region in 2021 due to an increase in the incidence of chronic diseases, use of cutting-edge treatments, presence of key players, and rise in healthcare spending in the region
• Asia Pacific is expected to grow at the fastest CAGR over the projected period due to an uptick in R&D activity, an increase in disposable incomes, and a better understanding of protein therapies among patients
• India and China are additionally anticipated to see rapid growth in the Asia-Pacific region

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Trends & Outlook

3.2 Market Segmentation And Scope

3.3 Market Dynamics

3.3.1 Market Driver Analysis

3.3.1.1 Growing Research Activities For Drug Development And Precision Medicine

3.3.1.2 Rising Adoption Of Biologics And Biosimilars

3.3.1.3 Increasing Investments In Research & Development Activities

3.3.2 Market Restraint Analysis

3.3.2.1 Regulatory And Safety Concerns With Protein Production

3.3.2.2 Dearth Of Skilled Personnel And Expertise

3.3.3 Market Opportunity Analysis

3.3.3.1 Declining Cost Of Therapeutics Recombinant Proteins And Advent Of Biosimilars

3.3.3.2 Innovative Techniques Can Decrease The Recombinant Protein Production Cost

3.4 Business Environment Analysis Tools

3.4.1 Swot Analysis, By Pest

3.4.2 Porter’s Five Forces Analysis

3.5 Penetration & Growth Prospect Mapping For Product, 2021

3.6 Recombinant Proteins Market: Covid-19 Impact Analysis

Chapter 4 Product Segment Analysis

Chapter 5 Application Segment Analysis

Chapter 6 End-User Segment Analysis

Chapter 7 Host-Cells Segment Analysis

Chapter 8 Regional Outlook

Chapter 9 Competitive Landscape

9.1 Strategy Framework

9.2 Market Participation Categorization

9.3 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/2fs4zc

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900